ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 34

IL-23 Regulates Development of Spontaneous Germinal Centers and Pathogenic Autoantibody Production in BXD2 Mice

Huixian Hong1, Qi Wu2, PingAr Yang2, Bao Luo3, Jun Li4, Hao Li5, Daniel Cua6, Hui-Chen Hsu2 and John D. Mountz2,7, 1University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 3DIvision of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 5Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 6Discovery Research, Merck Research Laboratory, Palo Alto, CA, 7University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: B cells, IL-23 and autoantibodies

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Targeting IL-23 to treat autoimmune disease and chronic inflammation is currently in development based on its pro-inflammatory function via regulating the activation of Th17 cells. IL-23 was previously shown to be important for promoting pathogenic autoantibody production in Fas deficient B6-Faslpr/lpr mice, suggesting the positive role of IL-23 in mediating Fas-independent germinal center (GC) responses. In contrast, the lack of IL-23 did not influence conventional GC formation and IgG anti-CII autoantibodies in type II collagen immunized DBA/1 mice. We determined if IL-23 could regulate development of GCs and pathogenic autoantibody production in BXD2 mice.

Methods: The BXD2-IL-23 p19–⁄– mice were generated by 10 generation crossing the B6-p19–⁄– with the BXD2 mice. Serum autoantibodies were determined by ELISA. GC development was measured by FACS (GL-7 and Fas) and confocal imaging analyses. Autoantibody class switching was enumerated by the percentage of (IgM–IgD–) in GL-7+ B cells. Immune complex deposition (IgM and IgG) in kidney was detected by confocal imaging.

Results: There was lower induction of Il17a in subpopulations of spleen cells from BXD2-p19–⁄– mice compared to WT BXD2 mice. However, unlike BXD2-Il17ra–⁄– mice, which developed lower levels of both IgM and IgG autoantibodies, BXD2-p19–⁄– mice exhibited significantly elevated titer of total IgM and IgM anti-DNA and RF autoantibodies but significantly lower levels of total IgG and IgG anti-histone, compared to WT BXD2 mice. Despite the lower circulating IgG autoantibodies, IgG staining was significantly increased in the glomerulus of BXD2-p19–⁄– mice compared to BXD2 and normal B6 mice with both an immune complex and linear staining pattern. The number and size of PNA+ GCs and the percent of GL-7+Fas+ GC B cells were increased in BXD2-p19–⁄– mice comparable to WT BXD2 mice. Abnormal GC development kinetics was confirmed by increased conventional isotype switched IgM–IgD– GL7+Fas+ B cells in BXD2-p19–⁄– mice compared to BXD2 WT mice.

Conclusion: The present findings provide a potential link to consolidate previous findings on the importance of IL-23 in mediating IgG autoantibody development in B6-Faslpr/lpr mice and the lack of effects in development of IgG anti-CII antibody in CII immunized IL-23 deficient mice. These results extend the paradigm of IL-23 disease beyond the classical IL23-Th17 axis and suggest IL-23 exhibits a negative effect on development of classical GC B cells that produce highly pathogenic autoAbs.


Disclosure: H. Hong, None; Q. Wu, None; P. Yang, None; B. Luo, None; J. Li, None; H. Li, None; D. Cua, Merck Pharmaceuticals, 3; H. C. Hsu, NIH, 2; J. D. Mountz, NIH, 2.

To cite this abstract in AMA style:

Hong H, Wu Q, Yang P, Luo B, Li J, Li H, Cua D, Hsu HC, Mountz JD. IL-23 Regulates Development of Spontaneous Germinal Centers and Pathogenic Autoantibody Production in BXD2 Mice [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/il-23-regulates-development-of-spontaneous-germinal-centers-and-pathogenic-autoantibody-production-in-bxd2-mice/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-23-regulates-development-of-spontaneous-germinal-centers-and-pathogenic-autoantibody-production-in-bxd2-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology